Comment
doi: 10.1016/S0140-6736(18)32460-7.
Epub 2018 Oct 4.
Lorcaserin: balancing efficacy with potential risks
Affiliations
- PMID: 30293772
- DOI: 10.1016/S0140-6736(18)32460-7
Item in Clipboard
Comment
Lorcaserin: balancing efficacy with potential risks
Lancet.
.
No abstract available
Comment on
-
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.Lancet. 2018 Nov 24;392(10161):2269-2279. doi: 10.1016/S0140-6736(18)32328-6. Epub 2018 Oct 4. Lancet. 2018. PMID: 30293771 Clinical Trial.
Similar articles
-
Lorcaserin Hcl for the treatment of obesity.Expert Opin Pharmacother. 2015;16(16):2531-8. doi: 10.1517/14656566.2015.1096345. Epub 2015 Oct 15. Expert Opin Pharmacother. 2015. PMID: 26472579 Review.
-
Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin.Kidney Int. 2019 Jun;95(6):1287-1288. doi: 10.1016/j.kint.2019.03.002. Epub 2019 Mar 7. Kidney Int. 2019. PMID: 31029502 No abstract available.
-
Safety and tolerability review of lorcaserin in clinical trials.Clin Obes. 2016 Oct;6(5):285-95. doi: 10.1111/cob.12159. Clin Obes. 2016. PMID: 27627785 Review.
-
Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studies.Diabetes Obes Metab. 2016 Sep;18(9):945-8. doi: 10.1111/dom.12690. Epub 2016 Jun 22. Diabetes Obes Metab. 2016. PMID: 27173586 Clinical Trial.
-
Has the bloom gone out of lorcaserin following the CAMELLIA-TIMI61 trial?Expert Opin Pharmacother. 2021 Feb;22(3):261-264. doi: 10.1080/14656566.2020.1858795. Epub 2020 Dec 31. Expert Opin Pharmacother. 2021. PMID: 33382010 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
